ArticleESMO open2018

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Jaafar Bennouna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.